Login / Signup

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.

Yuan-Kai ShiJianying ZhouYanqiu ZhaoBo ZhuLiangming ZhangXingya LiJian FangJianhua ShiZhixiang ZhuangSheng YangDonglin WangHuiqing YuLongzhen ZhangRongsheng ZhengMichael GrecoTingting Wang
Published in: BMC medicine (2023)
ClinicalTrials.gov, NCT03386955.
Keyphrases
  • small cell lung cancer
  • squamous cell carcinoma
  • locally advanced
  • rectal cancer
  • clinical trial
  • neoadjuvant chemotherapy
  • tyrosine kinase
  • lymph node
  • brain metastases